{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:18:56Z","timestamp":1792642736641,"version":"4.5.0"},"reference-count":69,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Migraine is a potentially disabling disorder, yet it remains underdiagnosed and undertreated. The release of the neuropeptide calcitonin gene-related peptide (CGRP) in the trigemino-cerebrovascular system plays a vital role in the evolution of migraine. It enhances peripheral sensitization by mediating neurogenic inflammation and also influences central sensitization. The majority of the drug classes available for migraine prophylaxis are nonspecific and associated with numerous side effects and drug interactions. Anti-CGRP monoclonal antibodies (mAb) are an innovative therapeutic class that fulfills the need for more efficacious and tolerable preventive therapy. While erenumab is a mAb to the CGRP receptor, eptinezumab, fremanezumab, and galcanezumab bind to the CGRP molecule. They decrease the number of headache days and improve disability. Upper respiratory tract infection, nausea, constipation, pain at the site of injection, and fatigue are the associated side effects. CGRP mAbs are an excellent advancement in translational research and are a promising addition in migraine therapy. This article discusses the recent advances in the development of the CGRP mAbs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/sjmms.sjmms_95_22","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T04:30:16Z","timestamp":1679891416000},"page":"11-18","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":30,"title":["Advances in CGRP Monoclonal Antibodies as Migraine Therapy"],"prefix":"10.4103","volume":"11","author":[{"given":"Suruchi","family":"Aditya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Rattan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-2-20240909","doi-asserted-by":"crossref","first-page":"e00950","DOI":"10.1002\/brb3.950","article-title":"What is the actual prevalence of migraine?","volume":"8","author":"Yeh","year":"2018","journal-title":"Brain Behav"},{"key":"R3-2-20240909","first-page":"304921","article-title":"The migraine-ischemic stroke relation in young adults","volume":"2011","author":"Pezzini","year":"2010","journal-title":"Stroke Res Treat"},{"key":"R4-2-20240909","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0333102416631959","article-title":"Increase in migraine diagnoses and guideline-concordant treatment in veterans, 2004-2012","volume":"37","author":"Altalib","year":"2017","journal-title":"Cephalalgia"},{"key":"R5-2-20240909","first-page":"356","article-title":"Managing childhood migraine","volume":"44","author":"Sixsmith","year":"2015","journal-title":"Aust Fam Physician"},{"key":"R6-2-20240909","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1129-2377-15-31","article-title":"The impact of headache in Europe: Principal results of the Eurolight project","volume":"15","author":"Steiner","year":"2014","journal-title":"J Headache Pain"},{"key":"R7-2-20240909","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/2040622315579627","article-title":"The diagnosis and treatment of chronic migraine","volume":"6","author":"Weatherall","year":"2015","journal-title":"Ther Adv Chronic Dis"},{"key":"R8-2-20240909","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s11916-013-0370-7","article-title":"Migraine and triggers: Post hoc ergo propter hoc?","volume":"17","author":"Hoffmann","year":"2013","journal-title":"Curr Pain Headache Rep"},{"key":"R9-2-20240909","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1042\/ETLS20200018","article-title":"Fremanezumab: A disease-specific option for the preventive treatment of migraine, including difficult-to-treat migraine","volume":"4","author":"Friedman","year":"2020","journal-title":"Emerg Top Life Sci"},{"key":"R10-2-20240909","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s10194-019-1038-4","article-title":"Current and emerging evidence-based treatment options in chronic migraine: A narrative review","volume":"20","author":"Agostoni","year":"2019","journal-title":"J Headache Pain"},{"key":"R11-2-20240909","doi-asserted-by":"crossref","first-page":"1756286420927119","DOI":"10.1177\/1756286420927119","article-title":"The role of erenumab in the treatment of migraine","volume":"13","author":"Andreou","year":"2020","journal-title":"Ther Adv Neurol Disord"},{"key":"R12-2-20240909","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1474-4422(13)70051-6","article-title":"Vasodilation out of the picture as a cause of migraine headache","volume":"12","author":"Charles","year":"2013","journal-title":"Lancet Neurol"},{"key":"R13-2-20240909","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1146\/annurev-pharmtox-010814-124701","article-title":"Calcitonin gene-related peptide (CGRP): A new target for migraine","volume":"55","author":"Russo","year":"2015","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R14-2-20240909","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/j.pain.0000000000000831","article-title":"The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine","volume":"158","author":"Iyengar","year":"2017","journal-title":"Pain"},{"key":"R15-2-20240909","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s10194-017-0811-5","article-title":"Triptans and CGRP blockade \u2013 Impact on the cranial vasculature","volume":"18","author":"Benemei","year":"2017","journal-title":"J Headache Pain"},{"key":"R16-2-20240909","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2165\/11534920-000000000-00000","article-title":"Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine","volume":"24","author":"Durham","year":"2010","journal-title":"CNS Drugs"},{"key":"R17-2-20240909","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1212\/WNL.0b013e3182a6cb72","article-title":"Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine","volume":"81","author":"Cernuda-Moroll\u00f3n","year":"2013","journal-title":"Neurology"},{"key":"R18-2-20240909","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/head.13439","article-title":"Basic considerations for the use of monoclonal antibodies in migraine","volume":"58","author":"Levin","year":"2018","journal-title":"Headache"},{"key":"R19-2-20240909","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s10194-019-1009-9","article-title":"Shaping the future of migraine targeting calcitonin-gene-related-peptide with the disease-modifying migraine drugs (DMMDs)","volume":"20","author":"Martelletti","year":"2019","journal-title":"J Headache Pain"},{"key":"R20-2-20240909","first-page":"973","article-title":"Preventive migraine treatment","volume":"21","author":"Silberstein","year":"2015","journal-title":"Continuum (Minneap Minn"},{"key":"R22-2-20240909","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1526-4610.2012.02140.x","article-title":"Opioids should not be used in migraine","volume":"52","author":"Tepper","year":"2012","journal-title":"Headache"},{"key":"R23-2-20240909","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s10194-019-1010-3","article-title":"Optimising migraine treatment: From drug-drug interactions to personalized medicine","volume":"20","author":"Pomes","year":"2019","journal-title":"J Headache Pain"},{"key":"R24-2-20240909","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s42466-020-00057-1","article-title":"Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor: Addition to the S1 guideline: Therapy of migraine attacks and prevention of migraine. Recommendations of the Germany society of neurology and the German migraine and headache society","volume":"2","author":"Diener","year":"2020","journal-title":"Neurol Res Pract"},{"key":"R25-2-20240909","doi-asserted-by":"crossref","first-page":"2150132720959935","DOI":"10.1177\/2150132720959935","article-title":"Clinician-patient dialogue about preventive chronic migraine treatment","volume":"11","author":"Blumenfeld","year":"2020","journal-title":"J Prim Care Community Health"},{"key":"R26-2-20240909","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s10194-018-0955-y","article-title":"European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention","volume":"20","author":"Sacco","year":"2019","journal-title":"J Headache Pain"},{"key":"R27-2-20240909","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s10194-020-01127-0","article-title":"A prospective real-world analysis of erenumab in refractory chronic migraine","volume":"21","author":"Lambru","year":"2020","journal-title":"J Headache Pain"},{"key":"R28-2-20240909","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bph.14075","article-title":"Update on the pharmacology of calcitonin\/CGRP family of peptides: IUPHAR Review 25","volume":"175","author":"Hay","year":"2018","journal-title":"Br J Pharmacol"},{"key":"R29-2-20240909","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s10194-018-0848-0","article-title":"The big CGRP flood \u2013 Sources, sinks and signalling sites in the trigeminovascular system","volume":"19","author":"Messlinger","year":"2018","journal-title":"J Headache Pain"},{"key":"R30-2-20240909","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1007\/s12031-020-01493-z","article-title":"Expression of the CGRP family of neuropeptides and their receptors in the trigeminal ganglion","volume":"70","author":"Edvinsson","year":"2020","journal-title":"J Mol Neurosci"},{"key":"R31-2-20240909","doi-asserted-by":"crossref","first-page":"10587","DOI":"10.1523\/JNEUROSCI.2211-17.2017","article-title":"Fremanezumab-A humanized monoclonal anti-CGRP antibody-inhibits thinly myelinated (A\u03b4) but not unmyelinated (C) meningeal nociceptors","volume":"37","author":"Melo-Carrillo","year":"2017","journal-title":"J Neurosci"},{"key":"R32-2-20240909","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/head.12179","article-title":"Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development","volume":"53","author":"Bigal","year":"2013","journal-title":"Headache"},{"key":"R33-2-20240909","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.npep.2015.03.006","article-title":"Migraine and neuropeptides","volume":"52","author":"Tajti","year":"2015","journal-title":"Neuropeptides"},{"key":"R34-2-20240909","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/bcp.12686","article-title":"CGRP as a neuropeptide in migraine: Lessons from mice","volume":"80","author":"Russo","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"R35-2-20240909","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/bph.13164","article-title":"Meningeal blood flow is controlled by H2 S-NO crosstalk activating a HNO-TRPA1-CGRP signalling pathway","volume":"173","author":"Dux","year":"2016","journal-title":"Br J Pharmacol"},{"key":"R36-2-20240909","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10194-009-0130-6","article-title":"Migraine pain: Reflections against vasodilatation","volume":"10","author":"Panconesi","year":"2009","journal-title":"J Headache Pain"},{"key":"R37-2-20240909","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/j.1526-4610.2007.00854.x","article-title":"Neuron-glia signaling in trigeminal ganglion: Implications for migraine pathology","volume":"47","author":"Thalakoti","year":"2007","journal-title":"Headache"},{"key":"R38-2-20240909","doi-asserted-by":"crossref","first-page":"1744806919832718","DOI":"10.1177\/1744806919832718","article-title":"Calcitonin gene-related peptide potentiated the excitatory transmission and network propagation in the anterior cingulate cortex of adult mice","volume":"15","author":"Li","year":"2019","journal-title":"Mol Pain"},{"key":"R39-2-20240909","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1152\/physrev.00034.2015","article-title":"Pathophysiology of migraine: A disorder of sensory processing","volume":"97","author":"Goadsby","year":"2017","journal-title":"Physiol Rev"},{"key":"R40-2-20240909","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s10194-019-0974-3","article-title":"Therapeutic novelties in migraine: New drugs, new hope?","volume":"20","author":"Do","year":"2019","journal-title":"J Headache Pain"},{"key":"R41-2-20240909","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s10194-017-0807-1","article-title":"Blocking CGRP in migraine patients \u2013 A review of pros and cons","volume":"18","author":"Deen","year":"2017","journal-title":"J Headache Pain"},{"key":"R42-2-20240909","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s10194-018-0923-6","article-title":"Early onset of efficacy with erenumab in patients with episodic and chronic migraine","volume":"19","author":"Schwedt","year":"2018","journal-title":"J Headache Pain"},{"key":"R43-2-20240909","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10072-019-03839-x","article-title":"Erenumab: From scientific evidence to clinical practice-the first Italian real-life data","volume":"40","author":"Barbanti","year":"2019","journal-title":"Neurol Sci"},{"key":"R44-2-20240909","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","article-title":"A controlled trial of erenumab for episodic migraine","volume":"377","author":"Goadsby","year":"2017","journal-title":"N Engl J Med"},{"key":"R45-2-20240909","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1177\/0333102418759786","article-title":"ARISE: A phase 3 randomized trial of erenumab for episodic migraine","volume":"38","author":"Dodick","year":"2018","journal-title":"Cephalalgia"},{"key":"R46-2-20240909","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1212\/WNL.90.15_supplement.S20.001","article-title":"Primary results of PROMISE -1(Prevention of Migraine via intravenous eptinezumab safety and efficacy-1) trial: A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of eptinezumab for prevention of frequent episodic migraines (S20.001)","volume":"90","author":"Saper","year":"2018","journal-title":"Neurology"},{"key":"R48-2-20240909","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1001\/jama.2018.4853","article-title":"Effect of fremanezumab compared with placebo for prevention of episodic migraine: A randomized clinical trial","volume":"319","author":"Dodick","year":"2018","journal-title":"JAMA"},{"key":"R49-2-20240909","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","article-title":"Fremanezumab for the preventive treatment of chronic migraine","volume":"377","author":"Silberstein","year":"2017","journal-title":"N Engl J Med"},{"key":"R50-2-20240909","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","article-title":"Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): A randomised, double-blind, placebo-controlled, phase 3b trial","volume":"394","author":"Ferrari","year":"2019","journal-title":"Lancet"},{"key":"R51-2-20240909","doi-asserted-by":"crossref","first-page":"e2487","DOI":"10.1212\/WNL.0000000000010600","article-title":"Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study","volume":"95","author":"Goadsby","year":"2020","journal-title":"Neurology"},{"key":"R52-2-20240909","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","article-title":"Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial","volume":"75","author":"Stauffer","year":"2018","journal-title":"JAMA Neurol"},{"key":"R53-2-20240909","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1177\/0333102418779543","article-title":"Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial","volume":"38","author":"Skljarevski","year":"2018","journal-title":"Cephalalgia"},{"key":"R54-2-20240909","doi-asserted-by":"crossref","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study","volume":"91","author":"Detke","year":"2018","journal-title":"Neurology"},{"key":"R55-2-20240909","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","article-title":"Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: A randomised, double-blind, placebo-controlled, phase 3b study","volume":"392","author":"Reuter","year":"2018","journal-title":"Lancet"},{"key":"R56-2-20240909","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3389\/fneur.2020.00417","article-title":"Erenumab in chronic migraine patients who previously failed five first-line oral prophylactics and onabotulinumtoxina: A dual-center retrospective observational study","volume":"11","author":"Raffaelli","year":"2020","journal-title":"Front Neurol"},{"key":"R57-2-20240909","doi-asserted-by":"crossref","first-page":"e2309","DOI":"10.1212\/WNL.0000000000007497","article-title":"Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial","volume":"92","author":"Tepper","year":"2019","journal-title":"Neurology"},{"key":"R58-2-20240909","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1177\/0333102419854082","article-title":"Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine","volume":"39","author":"Ashina","year":"2019","journal-title":"Cephalalgia"},{"key":"R59-2-20240909","doi-asserted-by":"crossref","first-page":"FDD14","DOI":"10.4155\/fdd-2019-0018","article-title":"Calcitonin gene-related peptide: The new era of migraine therapy","volume":"1","author":"Macone","year":"2019","journal-title":"Future Drug Discov"},{"key":"R61-2-20240909","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s10194-018-0951-2","article-title":"Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: Data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies","volume":"19","author":"F\u00f6rderreuther","year":"2018","journal-title":"J Headache Pain"},{"key":"R62-2-20240909","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.2147\/PPA.S182563","article-title":"Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: Results from a 12-month open-label study in patients with migraine","volume":"12","author":"Ford","year":"2018","journal-title":"Patient Prefer Adherence"},{"key":"R63-2-20240909","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12883-018-1193-2","article-title":"A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine","volume":"18","author":"Camporeale","year":"2018","journal-title":"BMC Neurol"},{"key":"R64-2-20240909","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","article-title":"Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): A multicentre, randomised, double-blind, placebo-controlled, phase 3b trial","volume":"19","author":"Mulleners","year":"2020","journal-title":"Lancet Neurol"},{"key":"R66-2-20240909","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s10194-020-01213-3","article-title":"Association between response to triptans and response to erenumab: Real-life data","volume":"22","author":"Frattale","year":"2021","journal-title":"J Headache Pain"},{"key":"R67-2-20240909","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s10194-019-1018-8","article-title":"Erenumab and galcanezumab in chronic migraine prevention: Effects after treatment termination","volume":"20","author":"Raffaelli","year":"2019","journal-title":"J Headache Pain"},{"key":"R69-2-20240909","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s13311-018-0622-7","article-title":"The biology of monoclonal antibodies: Focus on calcitonin gene-related peptide for prophylactic migraine therapy","volume":"15","author":"Raffaelli","year":"2018","journal-title":"Neurotherapeutics"},{"key":"R70-2-20240909","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1007\/s00415-019-09673-7","article-title":"Placebo and nocebo phenomena in anti- CGRP monoclonal antibody trials for migraine prevention: A meta-analysis","volume":"267","author":"Kokoti","year":"2020","journal-title":"J Neurol"},{"key":"R71-2-20240909","first-page":"e4796","article-title":"The role of anti-calcitonin gene-related peptide in migraine and its implication in developing countries: A reasonable option to consider despite higher cost","volume":"11","author":"Akhtar","year":"2019","journal-title":"Cureus"},{"key":"R72-2-20240909","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s10194-017-0750-1","article-title":"The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: A systematic review and meta-analysis","volume":"18","author":"Hou","year":"2017","journal-title":"J Headache Pain"},{"key":"R73-2-20240909","first-page":"58","article-title":"CGRP monoclonal antibodies for chronic migraine: Year 1 of clinical use","volume":"19","author":"Robbins","year":"2020","journal-title":"Pract Pain Manag"},{"key":"R74-2-20240909","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s10194-020-01214-2","article-title":"Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment \u2013 Real world outcomes","volume":"22","author":"Talbot","year":"2021","journal-title":"J Headache Pain"},{"key":"R75-2-20240909","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1111\/head.13930","article-title":"Safety of rimegepant, an oral CGRP receptor antagonist, plus CGRP monoclonal antibodies for migraine","volume":"60","author":"Berman","year":"2020","journal-title":"Headache"}],"container-title":["Saudi Journal of Medicine &amp; Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/sjmms.sjmms_95_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:12:09Z","timestamp":1787166729000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/sjmms.sjmms_95_22"}},"subtitle":["A Narrative Review"],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/sjmms.sjmms_95_22","relation":{},"ISSN":["1658-631X"],"issn-type":[{"value":"1658-631X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]}}}